Hematological Side Effects of <sup>177</sup>Lu-DOTA-TATE Therapy in Patients with NENs
<b>Background/Objectives</b>: Lutathera<sup>®</sup> ([<sup>177</sup>Lu]Lu-DOTA-TATE) is the first radiolabelled somatostatin (SST) analog approved for the treatment of patients with well-differentiated (G1 and G2) unresectable or metastatic gastro-entero-pancreati...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-12-01
|
| Series: | Hemato |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2673-6357/6/1/1 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850090633795993600 |
|---|---|
| author | Luciano Carideo Rosaria Meucci Giuseppe Campagna Vincenzo Marcello Russo Enrico D’Ippolito Maria Rinzivillo Francesco Panzuto Daniela Prosperi |
| author_facet | Luciano Carideo Rosaria Meucci Giuseppe Campagna Vincenzo Marcello Russo Enrico D’Ippolito Maria Rinzivillo Francesco Panzuto Daniela Prosperi |
| author_sort | Luciano Carideo |
| collection | DOAJ |
| description | <b>Background/Objectives</b>: Lutathera<sup>®</sup> ([<sup>177</sup>Lu]Lu-DOTA-TATE) is the first radiolabelled somatostatin (SST) analog approved for the treatment of patients with well-differentiated (G1 and G2) unresectable or metastatic gastro-entero-pancreatic neuro-endocrine-neoplasms (GEP-NENs). The bone marrow and kidneys are critical organs for RLT with [<sup>177</sup>Lu]Lu-DOTA-TATE. Our purpose was to evaluate hematological and renal toxicity in 29 patients (18 males, 11 females) treated with Lutathera<sup>®</sup>. <b>Methods</b>: According to standard protocols, four cycles of (<sup>177</sup>Lu)Lu-DOTA-TATE were administered every eight/nine weeks. Patients received pre-medication with anti-emetic and anti-acid drugs and a slow amino acid infusion for renal protection. Blood count and serum creatinine data were collected at three time points: before the first cycle, after the second cycle, and at the end of treatment. <b>Results</b>: We found that almost all hematological parameters significantly decreased between the baseline and/or interim and post-therapy evaluation, although without a clinical impact. The presence of total tumor load or bone metastases had no influence on these findings, while male patients showed less hematological toxicity than females. Conversely, creatinine levels did not vary during treatment. <b>Conclusions</b>: Our study confirms that [<sup>177</sup>Lu]Lu-DOTATATE RLT is safe and well tolerated despite some minor (grade 1) hematological toxicity. |
| format | Article |
| id | doaj-art-619920c8a8c44f27b3b13bbdd09b190a |
| institution | DOAJ |
| issn | 2673-6357 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Hemato |
| spelling | doaj-art-619920c8a8c44f27b3b13bbdd09b190a2025-08-20T02:42:31ZengMDPI AGHemato2673-63572024-12-0161110.3390/hemato6010001Hematological Side Effects of <sup>177</sup>Lu-DOTA-TATE Therapy in Patients with NENsLuciano Carideo0Rosaria Meucci1Giuseppe Campagna2Vincenzo Marcello Russo3Enrico D’Ippolito4Maria Rinzivillo5Francesco Panzuto6Daniela Prosperi7Nuclear Medicine Unit, University Hospital Sant’Andrea, 00189 Rome, ItalyNuclear Medicine Unit, University Hospital Sant’Andrea, 00189 Rome, ItalyNuclear Medicine Unit, Department of Medical-Surgical Sciences and of Translational Medicine, Faculty of Medicine and Psychology, “Sapienza” University, 00189 Rome, ItalyNuclear Medicine Unit, Department of Medical-Surgical Sciences and of Translational Medicine, Faculty of Medicine and Psychology, “Sapienza” University, 00189 Rome, ItalyNuclear Medicine Unit, Department of Medical-Surgical Sciences and of Translational Medicine, Faculty of Medicine and Psychology, “Sapienza” University, 00189 Rome, ItalyGastroenterology Unit, Department of Medical-Surgical Sciences and of Translational Medicine, Faculty of Medicine and Psychology, “Sapienza” University, 00189 Rome, ItalyGastroenterology Unit, Department of Medical-Surgical Sciences and of Translational Medicine, Faculty of Medicine and Psychology, “Sapienza” University, 00189 Rome, ItalyNuclear Medicine Unit, University Hospital Sant’Andrea, 00189 Rome, Italy<b>Background/Objectives</b>: Lutathera<sup>®</sup> ([<sup>177</sup>Lu]Lu-DOTA-TATE) is the first radiolabelled somatostatin (SST) analog approved for the treatment of patients with well-differentiated (G1 and G2) unresectable or metastatic gastro-entero-pancreatic neuro-endocrine-neoplasms (GEP-NENs). The bone marrow and kidneys are critical organs for RLT with [<sup>177</sup>Lu]Lu-DOTA-TATE. Our purpose was to evaluate hematological and renal toxicity in 29 patients (18 males, 11 females) treated with Lutathera<sup>®</sup>. <b>Methods</b>: According to standard protocols, four cycles of (<sup>177</sup>Lu)Lu-DOTA-TATE were administered every eight/nine weeks. Patients received pre-medication with anti-emetic and anti-acid drugs and a slow amino acid infusion for renal protection. Blood count and serum creatinine data were collected at three time points: before the first cycle, after the second cycle, and at the end of treatment. <b>Results</b>: We found that almost all hematological parameters significantly decreased between the baseline and/or interim and post-therapy evaluation, although without a clinical impact. The presence of total tumor load or bone metastases had no influence on these findings, while male patients showed less hematological toxicity than females. Conversely, creatinine levels did not vary during treatment. <b>Conclusions</b>: Our study confirms that [<sup>177</sup>Lu]Lu-DOTATATE RLT is safe and well tolerated despite some minor (grade 1) hematological toxicity.https://www.mdpi.com/2673-6357/6/1/1hematological toxicityneuroendocrine tumorsnuclear medicine therapy<sup>177</sup>Lu-DOTA-TATEbone marrow irradiation |
| spellingShingle | Luciano Carideo Rosaria Meucci Giuseppe Campagna Vincenzo Marcello Russo Enrico D’Ippolito Maria Rinzivillo Francesco Panzuto Daniela Prosperi Hematological Side Effects of <sup>177</sup>Lu-DOTA-TATE Therapy in Patients with NENs Hemato hematological toxicity neuroendocrine tumors nuclear medicine therapy <sup>177</sup>Lu-DOTA-TATE bone marrow irradiation |
| title | Hematological Side Effects of <sup>177</sup>Lu-DOTA-TATE Therapy in Patients with NENs |
| title_full | Hematological Side Effects of <sup>177</sup>Lu-DOTA-TATE Therapy in Patients with NENs |
| title_fullStr | Hematological Side Effects of <sup>177</sup>Lu-DOTA-TATE Therapy in Patients with NENs |
| title_full_unstemmed | Hematological Side Effects of <sup>177</sup>Lu-DOTA-TATE Therapy in Patients with NENs |
| title_short | Hematological Side Effects of <sup>177</sup>Lu-DOTA-TATE Therapy in Patients with NENs |
| title_sort | hematological side effects of sup 177 sup lu dota tate therapy in patients with nens |
| topic | hematological toxicity neuroendocrine tumors nuclear medicine therapy <sup>177</sup>Lu-DOTA-TATE bone marrow irradiation |
| url | https://www.mdpi.com/2673-6357/6/1/1 |
| work_keys_str_mv | AT lucianocarideo hematologicalsideeffectsofsup177supludotatatetherapyinpatientswithnens AT rosariameucci hematologicalsideeffectsofsup177supludotatatetherapyinpatientswithnens AT giuseppecampagna hematologicalsideeffectsofsup177supludotatatetherapyinpatientswithnens AT vincenzomarcellorusso hematologicalsideeffectsofsup177supludotatatetherapyinpatientswithnens AT enricodippolito hematologicalsideeffectsofsup177supludotatatetherapyinpatientswithnens AT mariarinzivillo hematologicalsideeffectsofsup177supludotatatetherapyinpatientswithnens AT francescopanzuto hematologicalsideeffectsofsup177supludotatatetherapyinpatientswithnens AT danielaprosperi hematologicalsideeffectsofsup177supludotatatetherapyinpatientswithnens |